SCHEMBL2801670

SCHEMBL2801670

CCS(=O)(=O)NC(=O)c1cnn2c(Nc3cc(C)ccc3F)c(C(=O)N3CCC(c4ccc(F)cc4)CC3)cnc12

nearest known ligand 0.39

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
FASN P49327 7/20 0.39
MAPT P10636 2/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
THRB P10828 1/20 0.36
ALDH1A1 P00352 1/20 0.35
GPBAR1 Q8TDU6 1/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
EGLN1 Q9GZT9 2/20 0.34
RUVBL1 Q9Y265 1/20 0.34
RECQL P46063 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2799537 0.94 RECQL (0.36) FASNMAPTLMNATP53THRB
SCHEMBL2803803 0.94 FASN (0.40) FASNMAPTLMNATP53THRB
SCHEMBL2800842 0.94 ALDH1A1 (0.38) FASNMAPTTP53ALDH1A1NPC1
SCHEMBL2803063 0.93 FASN (0.39) FASNLMNATP53ALDH1A1EGLN1
SCHEMBL2801339 0.91 TP53 (0.38) MAPTLMNATP53THRB
SCHEMBL2803080 0.91 FASN (0.39) FASNMAPTLMNATP53THRB
SCHEMBL2802313 0.91 EGLN1 (0.35) FASNLMNAALDH1A1NPC1RAB9A
SCHEMBL2799817 0.90 FASN (0.36) FASNMAPTLMNATP53THRB
SCHEMBL2802170 0.90 FASN (0.41) FASNALDH1A1GPBAR1EGLN1
SCHEMBL2799735 0.89 FASN (0.40) FASNMAPTLMNATP53THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160008362-A1 AGENT FOR PREVENTING AND/OR TREATING OCULAR INFLAMMATORY DISEASE KYOWA HAKKO KIRIN CO., LTD. (JP) 2016-01-14 US claimed
EP-2962692-A1 AGENT FOR PREVENTING AND/OR TREATING OCULAR INFLAMMATORY DISEASE Kyowa Hakko Kirin Co., Ltd. (JP) 2016-01-06 EP claimed
US-8729264-B2 Agent for prevention and/or treatment of skin diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-05-20 US claimed
US-20160008362-A1 AGENT FOR PREVENTING AND/OR TREATING OCULAR INFLAMMATORY DISEASE KYOWA HAKKO KIRIN CO., LTD. (JP) 2016-01-14 US disclosed
EP-2962692-A1 AGENT FOR PREVENTING AND/OR TREATING OCULAR INFLAMMATORY DISEASE Kyowa Hakko Kirin Co., Ltd. (JP) 2016-01-06 EP disclosed
EP-2206714-B1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO LTD (JP) 2015-01-21 EP disclosed
US-8729264-B2 Agent for prevention and/or treatment of skin diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-05-20 US disclosed
US-20110105515-A1 TARGETING THE ONCOPROTEIN NUCLEOPHOSMIN PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-05-05 US disclosed
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
EP-2206714-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES Kyowa Hakko Kirin Co., Ltd. (JP) 2010-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105515-A1 TARGETING THE ONCOPROTEIN NUCLEOPHOSMIN NPM1, TP53, TP53BP1 FASN 4210/4885MAPT 1760/4885LMNA 2078/4885
US-20160008362-A1 AGENT FOR PREVENTING AND/OR TREATING OCULAR INFLAMMATORY DISEASE NR0B1, NR2E3, NR0B2 FASN 2967/4885MAPT 4767/4885LMNA 3855/4885
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES TYR, CUTA, SERPINB1 FASN 4286/4885MAPT 2533/4885LMNA 2418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.